Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease

American Journal of Gastroenterology

Volumn 108, Issue 12, 2013, Pages 1901-1910

  Däbritz, Jan ^a,b,c,d   Bonkowski, Erin ^e   Chalk, Claudia ^e   Trapnell, Bruce C ^e   Langhorst, Jost ^f   Denson, Lee A ^e   Foell, Dirk ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN S 100;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SENSITIVITY AND SPECIFICITY;

EID: 84889677565     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.360     Document Type: Article

References (38)

1. Crandall WV, Margolis PA, Kappelman MD et al. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics 2012; 129 : E1030-41.
2. Samson CM, Morgan P, Williams E et al. Improved outcomes with quality improvement interventions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2012; 55 : 679-88.
3. Siegel CA, Siegel LS, Hyams JS et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2011; 17 : 30-8.
4. Sartor RB. Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3 : 390-407.
5. Colombel JF, Sandborn WJ, Reinisch W et al. infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362 : 1383-95.
6. Egea L, McAllister CS, Lakhdari O et al. GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa. J Immunol 2013; 190 : 1702-13.
7. Egea L, Hirata Y, Kagnoff MF. GM-CSF: A role in immune and inflammatory reactions in the intestine. Expert Rev Gastroenterol Hepatol 2010; 4 : 723-31.
8. Bernasconi E, Favre L, Maillard MH et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote effi cient colonic mucosal healing. Inflamm Bowel Dis 2010; 16 : 428-41.
9. Dranoff G. Granulocyte-macrophage colony stimulating factor and inflammatory bowel disease: Establishing a connection. Gastroenterology 2011; 141 : 28-31.
10. Kelsen JR, Rosh J, Heyman M et al. Phase I trial of sargramostim in pediatric Crohn's disease. Inflamm Bowel Dis 2010; 16 : 1203-8.
11. Korzenik JR, Dieckgraefe BK, Valentine JF et al. Sargramostim for active Crohn's disease. N Engl J Med 2005; 352 : 2193-201.
12. Sainathan SK, Hanna EM, Gong Q et al. Granulocyte macrophage colonystimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis 2008; 14 : 88-99.
13. Valentine JF, Fedorak RN, Feagan B et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: A randomised, double-blind, placebo-controlled, phase 2 study. Gut 2009; 58 : 1354-62.
14. Watanabe M, Uchida K, Nakagaki K et al. High avidity cytokine autoantibodies in health and disease: Pathogenesis and mechanisms. Cytokine Growth Factor Rev 2010; 21 : 263-73.
15. Fudala R, Krupa A, Stankowska D et al. Anti-interleukin-8 autoantibody: Interleukin-8 immune complexes in acute lung injury/acute respiratory distress syndrome. Clin Sci (Lond) 2008; 114 : 403-12.
16. Rosenau BJ, Schur PH. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2009; 36 : 753-6.
17. Browne SK, Holland SM. Immunodefi ciency secondary to anticytokine autoantibodies. Curr Opin Allergy Clin Immunol 2010; 10 : 534-41.
18. Ebert EC, Das KM, Mehta V et al. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies. Clin Exp Immunol 2008; 154 : 325-31.
19. Han X, Uchida K, Jurickova I et al. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology 2009 ; 136 : 1261-71, e1- 3.
20. Nylund CM, DMello S, Kim MO et al. Granulocyte macrophage- colonystimulating factor autoantibodies and increased intestinal permeability in Crohn disease. J Pediatr Gastroenterol Nutr 2011; 52 : 542-8.
21. Jurickova I, Collins MH, Chalk C et al. Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte-macrophage colonystimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity. Clin Exp Immunol 2013; 172 : 455-65.
22. Gathungu G, Kim M, Ferguson JP et al. Granulocyte-macrophage colonystimulating factor auto-antibodies: A marker of aggressive crohn's disease. Inflamm Bowel Dis 2013; 19 : 1671-80.
23. Uchida K, Nakata K, Suzuki T et al. Granulocyte/macrophage- colonystimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009; 113 : 2547-56.
24. D ä britz J, Bonkowski E, Langhorst J et al. Granulocyte-macrophage colony stimulating factor autoantibodies and disease relapse in inflammatory bowel disease (abstract). Gastroenterology 2013 ; 144 : S767.
25. Dabritz J, Langhorst J, Lugering A et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis 2013; 19 : 1130-8.
26. Sandborn WJ, Feagan BG, Hanauer SB et al. A review of activity indices and effi cacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122 : 512-30.
27. Hyams JS, Ferry GD, Mandel FS et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12 : 439-47.
28. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 1989; 298 : 82-6.
29. Turner D, Otley AR, Mack D et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study. Gastroenterology 2007; 133 : 423-32.
30. Foell D, Kucharzik T, Kraft M et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52 : 847-53.
31. Danese S. New therapies for inflammatory bowel disease: From the bench to the bedside. Gut 2012; 61 : 918-32.
32. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: From occult blood to molecular markers of intestinal inflammation and damage. Gut 2009; 58 : 859-68.
33. Judd TA, Day AS, Lemberg DA et al. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol 2011; 26 : 1493-9.
34. Mao R, Xiao YL, Gao X et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18 : 1894-9.
35. Langhorst J, Boone J. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases. Drugs Today (Barc) 2012; 48 : 149-61.
36. Langhorst J, Elsenbruch S, Koelzer J et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103 : 162-9.
37. D ä britz J, Langhorst J, Luegering A et al. Multicentre follow-up study of phagocyte-derived S100A12 as a surrogate marker of intestinal inflammation in inflammatory bowel disease [abstract]. Gastroenterology 2012 ; 142 : S781.
38. Costa F, Mumolo MG, Ceccarelli L et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54 : 364-8.